0001213900-23-015401 | F-1/A | XBRL Viewer

SFr 316,757

SFr 4,353

^[1]

410,918

219,315

^[2]

(726,442)

93,089

Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]

1,233

316,757

Loans [Member]

523,920

^[1]

(50,000)

1,522,931

^[2]

(473,920)

(999,011)

Lease liabilities [Member]

523,920

Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]

^[1]

(21,700)

^[2]

597,436

Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]

575,736

Total [Member]

840,677

4,353

^[1]

(71,700)

1,522,931

410,918

219,315

^[2]

(602,926)

(905,922)

Disclosure of Accrued expenses [Abstract]

SFr 576,969

SFr 840,677

[1]	The financing cash flows are from loan borrowings or loan and lease repayments.
[2]	Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.

Accrued expenses (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of accrued expenses

	December 31, 2021		December 31, 2020
Accrued research and development costs including milestone payments		557,391		1,105,089
Professional fees		179,461		172,273
Accrued vacation & overtime		51,218		44,466
Employee benefits incl. share based payments		196,917		101,821
Other		63,588		9,457
Total accrued expenses		1,048,575		1,433,106

Segment information

12 Months Ended

Dec. 31, 2021

Disclosure Of Entitys Operating Segments Text Block Abstract

Segment information

6. Segment information

Geographical information

The Group’s non-current assets by the Company’s country of domicile were as follows:

	December 31, 2021		December 31, 2020
Switzerland		14,734,738		9,030,778
Australia		144,854		151,269
Total		14,879,592		9,182,047

Non-current assets exclude financial instruments.

Employee Benefits (Details) - Schedule of defined benefit plan expense recognized in profit or loss - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Defined Benefit Plan Expense Recognized In Profit Or Loss Abstract
Salaries	SFr 1,439,578	SFr 812,158	SFr 1,865,633	SFr 1,260,359	SFr 1,832,382
Pension costs			165,801	156,843	130,792
Other social benefits			275,258	116,290	217,448
Share based payments costs			1,223,696	351,401	226,601
Other personnel expenditures			214,940	47,295	(22,973)
Total employee benefits	SFr 1,910,528	SFr 2,105,007	SFr 3,745,328	SFr 1,932,188	SFr 2,384,250

Reporting entity

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Disclosure Of Reporting Entity Explanatory Abstract

Reporting entity

1.	Reporting entity

Altamira Therapeutics Ltd. (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. On October 25, 2022, the Company effected a one-for-twenty reverse share split (the “2022 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2022 Reverse Share Split, as if such 2022 Reverse Share Split occurred on the first day of the periods presented.

These condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities:

●

Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000

●

Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of USD 100

●

Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

●

Zilentin AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Auris Medical Pty Ltd, Collingwood, Australia (100%) with a nominal share capital of AUD 100

●

Altamira Medica AG, Zug, Switzerland (100%) with a nominal share capital of CHF 3,000,000

The Group is primarily involved in the development of novel products that address important unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics. The Group is focusing on the development of RNA therapeutics for extrahepatic therapeutic targets (AM-401 and AM-411), nasal sprays for protection against airborne viruses and allergens (AM-301; Bentrio™) or the treatment of vertigo (AM-125), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (AM-101; Keyzilen^®and AM-111; Sonsuvi^®).

1. Reporting entity

Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) (the “Company”) is an exempted company incorporated in Bermuda and is subject to Bermuda law. The Company’s registered address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities:

●

Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000

●

Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Zilentin AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000

●

Altamira Medica AG, Zug, Switzerland (100%), with a nominal share capital of CHF 3,000,000

●

Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of USD 100

●

Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

●

Auris Medical Pty Ltd, Collingwood, Australia (100%), with a nominal share capital of AUD 100

On March 13, 2018, the former Auris Medical Holding Ltd. merged (the “Merger”) into Auris Medical NewCo Holding AG (“Auris NewCo”), a newly incorporated, wholly-owned Swiss subsidiary following shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76, divided into 6,117,388 (pre-2019 Reverse Share Split) common shares with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) of Auris NewCo for every 10 of the Company’s common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10-for-1. Auris NewCo changed its name to “Auris Medical Holding AG” following consummation of the Merger. Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). The common shares of Auris Medical Holding Ltd. traded on the Nasdaq Capital Market under the trading symbol “EARS.” On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”.

The Company is primarily involved in the development of therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for delivery to extrahepatic targets (with AM-401 targeting KRAS driven cancers as first project, preclinical stage), the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2). Through its affiliate Altamira Medica, the Company is commercializing a nasal spray for protection against airborne viruses and allergens (AM-301).

Write-Down of Inventories

6 Months Ended

Jun. 30, 2022

Write-Down of Inventories [Abstract]

Write-down of inventories

7.	Write-down of inventories

The Company’s inventory consists of the product Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. Bentrio has a limited shelf life, which may affect the salability of the product, and is packaged in various configurations (stock keeping units, “SKUs”) for different markets. During the six months ended June 30, 2022, the Company wrote down finished goods inventories by CHF 764,844, based on a management review for any obsolete or slow-moving items. The write-down is included in Cost of Sales in the condensed consolidated statement of profit or loss and other comprehensive income. There were no inventory write-downs recognized during the six months ended June 30, 2021.

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) (Parentheticals) - SFr / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statement Of Profit Or Loss And Other Comprehensive Income Loss Abstract
Diluted loss per share	SFr (9.43)	SFr (10.85)	SFr (1.31)	SFr (1.36)	SFr (2.28)

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 460,710
Research and development	(8,939,037)
Total operating expenses	(15,137,338)
Operating loss	(17,099,793)
Loss before tax	(17,368,546)
Net loss attributable of owners of the Company	(17,390,166)
Total comprehensive loss attributable to owners of the Company	$ (17,124,410)
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ (26.26)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ (246,493)
Research and development	578,216
Total operating expenses	331,723
Operating loss	331,723
Loss before tax	331,723
Net loss attributable of owners of the Company	331,723
Total comprehensive loss attributable to owners of the Company	$ 331,723
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ 0.5
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 214,217
Research and development	(8,360,821)
Total operating expenses	(14,805,615)
Operating loss	(16,768,070)
Loss before tax	(17,036,823)
Net loss attributable of owners of the Company	(17,058,443)
Total comprehensive loss attributable to owners of the Company	$ (16,792,687)
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ (25.76)

Share-based compensation (Details)	12 Months Ended
Share-based compensation (Details)	Dec. 31, 2021 CHF (SFr) SFr / shares shares	Dec. 31, 2021 CHE shares	Dec. 31, 2020 CHF (SFr) SFr / shares shares	Dec. 31, 2019 CHF (SFr) shares	Dec. 31, 2021 CHE	Dec. 31, 2019 CHE
Share-based compensation (Details) [Line Items]
Options granted (in Shares) \| shares	342,263	342,263	726,637	390,620
Share based payment \| SFr	SFr 1,206,303		SFr 368,793	SFr 228,920
Total expense recognized for equity-settled share-based payment transactions		CHE 1,223,696	351,401	SFr 226,601
Purchase of intangibles was capitalized			SFr 0		CHE 0	CHE 2,319
Bottom of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 0.75		SFr 0.73
Top of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 28.79		SFr 27.93

Employee Benefits (Details)	6 Months Ended				12 Months Ended
Employee Benefits (Details)	Jun. 30, 2022 CHF (SFr) shares	Jun. 30, 2022 $ / shares	Jun. 30, 2021 CHF (SFr) shares	Jun. 30, 2021 $ / shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee benefits [Abstract]
Share based compensation description					In 2021 share based compensation expense included CHF 902,817 for one regular and one extraordinary share bonus grant related to the strategic repositioning of the Company. The latter, which amounts to CHF 810,252, including CHF 360,112 for a future share grant contingent on achieving the Positive Results related to the Trasir transaction. Share based compensation included expense related to employee stock options of CHF 320,879 in the year 2021 compared to CHF 351,401 in 2020. On the other hand, expenses for salaries in the previous year had benefited from reimbursements of CHF 63,208 under the Swiss short-time work scheme, which had been used for three months in connection with a temporary reduction in project activities due to the COVID-19 pandemic.
Benefit plans interest rate					1.00%	1.00%	1.00%
Weighted average duration defined benefit obligation					19 years 10 months 24 days	21 years 10 months 24 days
Stock options	SFr 180,808		SFr 159,487
Share based compensation expense			810,252
Future share grant contingent			SFr 360,112
Granted options (in Shares) \| shares	27,861		6,862
Equity incentive plans (in Dollars per share) \| $ / shares		$ 20.8		$ 70.2

Trade and Other Payables

12 Months Ended

Dec. 31, 2021

Disclosure Of Trade And Other Payables Text Block Abstract

Trade and other payables

16. Trade and other payables

	December 31, 2021		December 31, 2020
Trade accounts payable - third parties		3,544,384		722,272
Other		153,339		40,181
Total trade and other payables		3,697,723		762,453

Financial instruments and risk management (Tables)

12 Months Ended

Dec. 31, 2021

Financial Instruments and Risk Management [Abstract]

Schedule of carrying amounts of financial assets and financial liabilities

	December 31, 2021		December 31, 2020
Financial assets
Cash and cash equivalents		984,191		11,258,870
Loans and receivables
Other non-current financial assets		199,105		20,001
Other receivables		255,187		10,040
Total financial assets		1,438,483		11,288,911

Financial liabilities
At amortized cost
Trade and other payables		3,697,723		762,453
Accrued expenses		1,048,575		1,433,106
Loan		—		523,920
Non-current lease liabilities		461,485		—
Current lease liabilities		114,251		—
At fair value through profit and loss
Derivative financial instruments		1,233		316,757
Total financial liabilities		5,323,267		3,036,236

Schedule of analysis the remaining contractual maturities of financial liabilities

	Carrying amount		Less than 3 months		Between 3 months and 2 years		2 years and later		Total
December 31, 2021
Trade and other payables		3,697,723		3,697,723		—		—		3,697,723
Accrued expenses		1,048,575		1,048,575		—		—		1,048,575
Loan and borrowings		—		—		—		—		—
Non-current lease liabilities		461,485		—		117,856		343,629		461,485
Current lease liabilities		114,251		28,231		86,020		—		114,251
Derivative financial instruments		1,233		—		—		1,233		1,233
Total		5,323,267		4,774,529		203,876		344,862		5,323,267

	Carrying amount		Less than 3 months		Between 3 months and 2 years		2 years and later		Total
December 31, 2020
Trade and other payables		762,453		762,453		—		—		762,453
Accrued expenses		1,433,106		1,433,106		—		—		1,433,106
Loan and borrowings		523,920		473,920		50,000				523,920
Derivative financial instruments		316,757		310,439		—		6,318		316,757
Total		3,036,236		2,979,918		50,000		6,318		3,036,236

Schedule of fair value measurement

Fair values as at

Fair

Financial assets / liabilities

December 31,
2021

December 31,
2020

value
hierarchy

Valuation technique(s) and key input(s)

Derivative financial liabilities – Warrants from public offerings

Liability

1,233

Liability
6,318

Level 2

Black-Scholes option pricing model

Derivative financial liabilities – Embedded derivatives

—

310,439

Level 3

Monte Carlo simulation model

Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan

	Dec 31, 2021				Dec 31, 2020
	Increase/Decrease in volatility assumption		Effect on result before taxes on CHF		Increase/Decrease in volatility assumption			Effect on result before taxes on CHF
Change in volatility		—		—		+5	%		2,770
		—		—		-5	%		-5,475

Schedule of changes in liabilities arising from financing activities

						Non-cash changes
	01.01.2021		Financing Cash Flows ¹⁾			Fair value revaluation		Other changes ²⁾			31.12.2021
Derivative financial instrument		316,757		—			410,918		(726,442	)		1,233
Loans		523,920		(50,000	)		—		(473,920	)		—
Lease liabilities		—		(21,700	)		—		597,436			575,736
Total		840,677		(71,700	)		410,918		(602,926	)		576,969

					Non-cash changes
	01.01.2020		Financing Cash Flows ¹⁾		Fair value revaluation		Other changes ²⁾			31.12.2020
Derivative financial instrument		4,353		—		219,315		93,089			316,757
Loans		—		1,522,931		—		(999,011	)		523,920
Total		4,353		1,522,931		219,315		(905,922	)		840,677

¹⁾	The financing cash flows are from loan borrowings or loan and lease repayments.
²⁾	Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.

Schedule of carrying amount of each financial asset in the consolidated statement of financial position

	December 31, 2021		December 31, 2020
Financial assets
Cash and cash equivalents		984,191		11,258,870
Trade receivables		21,746		—
Other receivables		255,187		10,040
Total		1,261,124		11,268,910

Schedule of financial assets and liabilities to currency risk

	2021								2020
in CHF	USD			EUR			AUD		USD			EUR
Cash and cash equivalents		388,950			539,474			—		9,214,709			694,287
Trade and other receivables		1,436,086			26,843			1,274,271		479			—
Trade and other payables		(104,676	)		(2,615,791	)		—		(75,712	)		(397,853	)
Accrued expenses		(163,823	)		(295,467	)		—		(34,648	)		(569,400	)
Net statement of financial position exposure -asset/(liability)		1,556,537			(2,344,941	)		1,274,271		9,104,828			(272,966	)

Significant accounting policies

12 Months Ended

Dec. 31, 2021

Significant accounting policies [Abstract]

Significant accounting policies

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated.

Basis of consolidation

Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Transactions eliminated on consolidation

All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Segment reporting

A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components.

The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for the treatment and prevention of ear, nose, throat and related disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.

Foreign currency

Foreign currency transactions

Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated.

Foreign operations

Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction).

These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.

Closing rates for the most significant foreign currencies relative to CHF:

Currency		Geographical area	Reporting entities		December 31, 2021		December 31, 2020		December 31, 2019
CHF	Swiss Franc	Switzerland		5		1.0000		1.0000		1.0000
USD	Dollar	United States		1		0.9110		0.8840		0.9674
EUR	Euro	Europe		1		1.0361		1.0817		1.0855
AUD	Dollar	Australia		1		0.6620		0.6822		—

Average exchange rates for the year for the most significant foreign currencies relative to CHF:

Currency		Geographical area	Reporting entities		2021		2020		2019
CHF	Swiss Franc	Switzerland		5		1.0000		1.0000		1.0000
USD	Dollar	United States		1		0.9142		0.9581		0.9938
EUR	Euro	Europe		1		1.0810		1.0825		1.1128
AUD	Dollar	Australia		1		0.6866		0.6546		—

Property and equipment

Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows:

Production equipment		5 years
Office furniture and electronic data processing equipment (“EDP”)		3 years

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use.

Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.

Intangible assets

Research and development

Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred.

Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it is the Group’s assessment that the criteria mentioned above are met and therefore direct development expenditures have been capitalized for AM-125 in 2019, 2020 and 2021. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, the costs for the prosecution and registration of patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. In case of AM-125, where in 2019 a US patent was issued and a related EU application was allowed, prosecution and registration costs have been capitalized as the criteria have been met.

Licenses, intellectual property and data rights

Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets.

Measurement

Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

Amortization

All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.

Impairment of non-financial assets

Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.

Asset purchase

On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery.

The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price.

Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of USD 4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license.

The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Group recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment.

Lease liabilities

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

Financial instruments

The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Recognition and derecognition of non-derivative financial assets and liabilities

The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date.

The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability.

The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired.

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

Non-derivative financial assets and liabilities—measurement

Loans and receivable

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses.

Cash and cash equivalents

The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents.

Non-derivative financial liabilities—measurement

Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

Convertible loans

In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method.

Share capital

All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement.

The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Repurchase and reissue of ordinary shares (treasury shares)

When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium.

Impairment of non-derivative financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence that financial assets are impaired includes:

●

default or delinquency by a debtor;

●

indications that a debtor or issuer will enter bankruptcy;

●

adverse changes in the payment status of borrowers or issuers;

●

the disappearance of an active market for a security; or

●

observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets.

Financial assets measured at amortized cost

The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.

Derivative Financial Instruments

Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement.

Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss.

Embedded Derivatives

Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when:

The host contract is not an asset in the scope of IFRS 9

The host contract is not itself carried at fair value through profit and loss (FVPL)

The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract

The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host

The separated embedded derivatives were measured at fair value by an independent consultant applying a simulation-based valuation approach. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss.

Income tax

Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date.

Deferred tax

Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for:

●

temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

●

temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and

●

taxable temporary differences arising on the initial recognition of goodwill.

Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis.

Employee benefits

The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States.

The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

Share-based compensation

The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations.

The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.

The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium.

Valuation of share options

Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.

Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Revenue recognition

Revenue from contracts with customers is recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. Revenue from the sale of products is recognized at the point in time when the customer obtains control of those products which is generally upon delivery at the customer. Revenue is net of value-added tax, rebates, discounts and returns.

Government grants

Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable.

The company obtains credits under the Australian R&D Tax Incentive program (R&DITC). The program provides a tax offset of 43.5% of eligible R&D expenditures. If the tax offset exceeds the Company’s tax liability, the balance is paid in cash after submission of a valid claim. Based on the specific features of the program, IAS 20 Government Grants is applied for the accounting treatment of the Australian R&DITC. The reimbursement application is made by the Company annually, once the fiscal year is closed, based on the financial statements. The income from grants related to R&D expenditures are presented separately under the heading of ‘other operating income’. Grants that relate to the acquisition of an asset are recognized in profit or loss as the asset is depreciated or amortized. These grants are recognized as a reduction in the cost of the asset.

Earnings/(loss) per share

Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

Capital and Reserves (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Capital and Reserves [Abstract]

Schedule of issued share capital

	Common Shares
	Number
	2022		2021
As of January 1		748,213		570,858
Common shares issued		105,000		111,299
Total, as of June 30		853,213		682,157

	December 31, 2021				December 31, 2020
	Number		CHF		Number		CHF
Common shares with a par value of CHF 0.01 each		14,964,261		149,643		11,417,159		114,172
Total		14,964,261		149,643		11,417,159		114,172

Schedule of common shares

	Common Shares (Number)
	2021		2020
As of January 1		11,417,159		4,125,949
Exercise of warrants		897,435		1,263,845
LPC equity line		—		1,610,120
ATM program		1,184,700		1,628,827
Share-based payments (bonus)		174,610		51,418
Conversion convertible loan		516,814		737,000
Shares issued for Trasir acquisition		773,543		—
Registered direct offering		—		2,000,000
Total, as of December 31		14,964,261		11,417,159

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	Altamira Therapeutics Ltd.
Document Type	F-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Central Index Key	0001601936
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Emerging Growth Company	false
Entity Address, Country	BM
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Postal Zip Code	HM 11
Entity Incorporation, State or Country Code	D0
Business Contact
Document Information Line Items
Entity Address, Country	DE
Entity Address, Address Line One	8 The Green
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Dover
Entity Address, Postal Zip Code	19901
Contact Personnel Name	Thomas Meyer

Cost of Sales (Tables)

12 Months Ended

Dec. 31, 2021

Cost of Sales [Abstract]

Schedule of cost of sales

	December 31, 2021		December 31, 2020		December 31, 2019
Product purchases, packaging and logistics		173,758		—		—
Employee benefit and expenses		89,238		—		—
Inventory write-down		1,977,558		—		—
Total cost of sales		2,240,554		—		—

Taxation (Details) - Schedule of tax loss carry forwards - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 109,855,150	SFr 114,013,858
Within 1 year [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	28,909,896	19,575,171
Between 1 and 3 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	50,673,943	56,866,795
Between 3 and 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	29,007,049	36,701,692
More than 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 1,264,262	SFr 870,200

Share-based compensation (Details) - Schedule of key terms and conditions related to the grants	12 Months Ended
	Dec. 31, 2021
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	279,771
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	523,881
Vesting conditions	2 years’ service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	523,881
Vesting conditions	3 years’ service from grant date (50%)
Contractual life of options	8 years

Condensed Consolidated Interim Statement of Changes in Equity (unaudited) - CHF (SFr)	SHARE CAPITAL	SHARE PREMIUM	Foreign Currency Translation Reserve	ACCUMULATED DEFICIT	FX TRANSLATION RESERVE	Total
Balance at Dec. 31, 2018	SFr 710,336	SFr 149,286,723	SFr (44,011)	SFr (146,303,398)		SFr 3,649,650
Total comprehensive loss
Net loss				(6,631,901)		(6,631,901)
Other comprehensive income/(loss)			16,446	(72,010)		(55,564)
Total comprehensive loss			16,446	(6,703,911)		(6,687,465)
Transactions with owners of the Company
Capital increase /Exercise of warrants	940,044	8,853,599				9,793,643
Transaction costs		(948,615)				(948,615)
Share based payments				228,920		228,920
Balance at Dec. 31, 2019	1,650,380	157,191,707	(27,565)	(152,778,389)		6,036,133
Total comprehensive loss
Net loss				(8,200,165)		(8,200,165)
Other comprehensive income/(loss)			88,862	(26,118)		62,744
Total comprehensive loss			88,862	(8,226,283)		(8,137,421)
Transactions with owners of the Company
Reduction par value	(1,973,044)	1,973,044
Capital increase /Exercise of warrants	429,466	15,645,530				16,074,996
Transaction costs		(636,858)				(636,858)
Conversion of loan	7,370	3,056,877				3,064,247
Share based payments				368,793		368,793
Balance at Dec. 31, 2020	114,172	177,230,300	61,297	(160,635,879)	SFr 61,297	16,769,890
Total comprehensive loss
Net loss				(6,754,579)		(6,754,579)
Other comprehensive income/(loss)				448,946	(41,922)	407,024
Total comprehensive loss				(6,305,633)	(41,922)	(6,347,555)
Transactions with owners of the Company
Capital increase /Exercise of warrants	8,974	3,885,764				3,894,738
Conversion of loan	5,168	1,366,087				1,371,255
Share based/Asset purchase	7,735	2,266,735		1,078,800		3,353,270
Share based payments	382	92,181		952,349		1,044,912
Balance at Jun. 30, 2021	136,431	184,841,067		(164,910,363)	19,375	20,086,510
Balance at Dec. 31, 2020	114,172	177,230,300	61,297	(160,635,879)	61,297	16,769,890
Total comprehensive loss
Net loss				(17,390,166)		(17,390,166)
Other comprehensive income/(loss)			772	264,984		265,756
Total comprehensive loss			772	(17,125,182)		(17,124,410)
Transactions with owners of the Company
Capital increase /Exercise of warrants	20,822	7,083,869				7,104,691
Transaction costs		(156,817)				(156,817)
Conversion of loan	5,168	1,366,087				1,371,255
Share based/Asset purchase	7,735	2,447,081		1,078,800		3,533,616
Share based payments	1,746	540,956		663,601		1,206,303
Balance (Previously Stated) at Dec. 31, 2021	149,643	188,511,476	SFr 62,069	(176,018,660)		12,704,528
Balance at Dec. 31, 2021	149,643	188,511,476		(175,686,937)	62,069	13,036,251
Total comprehensive loss
Net loss				(7,306,318)		(7,306,318)
Other comprehensive income/(loss)				209,526	(63,477)	146,049
Total comprehensive loss				(7,096,792)	(63,477)	(7,160,269)
Transactions with owners of the Company
Capital increase	21,000	1,597,374				1,618,374
Share based payments				180,808		180,808
Balance at Jun. 30, 2022	SFr 170,643	SFr 190,108,850		SFr (182,602,921)	SFr (1,408)	SFr 7,675,164

Right-of-use assets and lease liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Right Of Use Assets And Lease Liabilities Abstract

Schedule of right-of-use assets and lease liabilities

Right-of-use assets	Office building			Total
At cost
As of January 1, 2020		—			—
As of December 31, 2020		—			—
Additions		594,436			594,436
Disposals		—			—
As of December 31, 2021		594,436			594,436

Accumulated depreciation
As of January 1, 2020		—			—
As of December 31, 2020		—			—
Charge for the year		(29,722	)		(29,722	)
Disposals		—			—
As of December 31, 2021		(29,722	)		(29,722	)

Net book value
As of December 31, 2020		—			—
As of December 31, 2021		564,714			564,714

Schedule of low value and short-term lease expenses

Low value and short-term lease expenses	December 31, 2021		December 31, 2020

Expense related to short-term leases		52,280		61,509
Expense related to leases of low value assets		—		—
Total		52,280		61,509

Schedule of lease liabilities

Lease liabilities	December 31, 2021			December 31, 2020
As of January 1		—			—
Additions		594,436			—
Interest expenses		3,000			—
Repayment of lease liability		(21,700	)		—
As of December 31		575,736			—

thereof non-current		461,485			—
thereof current		114,251

Schedule of maturities of lease liabilities

Maturities of lease liabilities	December 31, 2021			December 31, 2020

Year 1		130,200			—
Year 2		130,200			—
Year 3		130,200			—
Year 4		130,200			—
Year 5		97,650			—
Undiscounted lease payments		618,450			—
Less: unearned interest		(42,714	)		—
Total		575,736			—

Other operating income

12 Months Ended

Dec. 31, 2021

Other operating income [Abstract]

Other operating income

18. Other operating income

	December 31, 2021		December 31, 2020		December 31, 2019
Income from R&D tax incentive (Government grants)		458,157		—		—
Refund of share issuance stamp duty		—		100,002		—
Other income		2,553		74,473		—
Total other operating income		460,710		174,475		—

Other operating income (Tables)

12 Months Ended

Dec. 31, 2021

Other operating income [Abstract]

Schedule of other operating income

	December 31, 2021		December 31, 2020		December 31, 2019
Income from R&D tax incentive (Government grants)		458,157		—		—
Refund of share issuance stamp duty		—		100,002		—
Other income		2,553		74,473		—
Total other operating income		460,710		174,475		—

Basis of preparation (Details)	1 Months Ended	6 Months Ended		12 Months Ended
Basis of preparation (Details)	Oct. 21, 2022 USD ($)	Jun. 30, 2022 CHF (SFr)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Basis of preparation (Details) [Line Items]
Reverse stock split				The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20.
Tax asset					$ 31,879	$ 476,363
Intangible asset (in Francs) \| SFr		SFr 15,851,501		SFr 14,314,877
Agreement description		The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares.	The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares.
Sale percentage of share capital	90.00%
Cash consideration	$ 1,000,000
Total, cash consideration	2,000,000
Additional subsidiaries upfront payment	25,000,000
Upfront payment increasing per month amount	$ 1,000,000
Unconverted outstanding loan amount		SFr 4,701,906	$ 25,000,000
Capitalized development costs (in Francs) \| SFr		SFr 12,000,000
Bottom of range [Member]
Basis of preparation (Details) [Line Items]
Tax losses years				7 years
Option to purchase percentage		90.00%	90.00%
Not yet received initial amount			$ 2,000,000
Top of range [Member]
Basis of preparation (Details) [Line Items]
Tax losses years				20 years
Option to purchase percentage		100.00%	100.00%
Not yet received initial amount			$ 2,200,000

Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) - SFr / shares	Dec. 31, 2021	Dec. 31, 2020
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.01	SFr 0.01

General and administrative expense (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of general and administrative expense [Abstract]

Schedule of general and administrative expense

	December 31, 2021		December 31, 2020			December 31, 2019
Employee benefits and expenses		1,554,778		811,373			1,010,708
Business development		967,046		95,663			113,959
Travel expenses		75,829		28,898			102,679
Administration expenses		2,245,862		1,645,530			2,653,914
Lease expenses from short-term lease		52,280		13,871			27,362
Depreciation Right-of-use assets		29,722		—			—
Depreciation tangible assets		—		3,555			10,740
Capital tax expenses		21,059		(4,228	)		14,501
Total general and administrative expenses		4,946,576		2,594,662			3,933,863

Inventories (Details) - Schedule of Inventories SFr in Millions	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)
Schedule Of Inventories Abstract
Finished goods	SFr 2.0	$ 839,221
Total		$ 839,221

Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 AUD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,556,537	€ (2,344,941)	$ 1,274,271	$ 9,104,828	€ (272,966)
Cash and cash equivalents [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	388,950	539,474		9,214,709	694,287
Other Receivables [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	1,436,086	26,843	1,274,271	479
Trade and other payables [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(104,676)	(2,615,791)		(75,712)	(397,853)
Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ (163,823)	€ (295,467)		$ (34,648)	€ (569,400)

Taxation (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Disclosure of Taxation [Abstract]

Schedule of income tax expense

	SIX MONTHS ENDED
	June 30,			June 30,
	2022			2021
Current income tax expense		(1,231	)		—
Deferred income tax gain		47,316			10,642
Total income tax (expense)/gain		46,085			10,642

	2021			2020			2019
Deferred income tax expense		(570,730	)		(389,384	)		(213,355	)
Deferred income tax gain		549,110			410,668			407,192
		(21,620	)		21,284			193,837

Schedule of effective income tax expense

Reconciliation	2021			2020			2019
Loss before income tax		(17,368,546	)		(8,221,449	)		(6,825,738	)
Income tax at statutory tax rates applicable to results in the respective countries		2,348,057			991,120			854,636
Effect of unrecognized temporary differences		(632,031	)		(302,557			89,974
Effect of unrecognized taxable losses		(1,885,486	)		(184,881	)		(913,309	)
Effect of utilization of previously unrecognized taxable losses		—			—			193,155
Effect of impairment of deferred tax assets		(75,375	)		—			(131,055	)
Effect of previously unrecognized deferred tax asset		—			97,458			20,977
Effect of expenses not considerable for tax purposes		—			(47,894	)		(29,549
Effect of changes in local tax legislation and/or local tax rates		—			—			110,758
Effect of impact from application of different tax rates		223,215			(531,962	)		(1,750	)
Income tax gain/(loss)		(21,620	)		21,284			193,837

Schedule of deferred income tax liabilities or to deferred income tax assets

Deferred Tax Liabilities	December 31, 2021			December 31, 2020
Intangible assets		(51,914	)		(252,174	)
Deferred unrealized foreign exchange gains		—			(350,054	)
Other receivables		(122,449	)		—
Total		(174,363	)		(602,228	)

Deferred Tax Asset	December 31, 2021			December 31, 2020
Net operating loss (NOL)		31,879			476,363
Total		31,879			476,363
Deferred Tax, net		(142,484	)		(125,865	)

Schedule of recognized tax benefits deferred tax

	June 30,			December 31,
	2022			2021
Deferred Tax liabilities
Intangible assets		(47,590	)		(51,914	)
Other receivables		(81,184	)		(122,449	)
Total		(128,774	)		(174,363	)
Deferred Tax assets
Net operation loss (NOL)		32,775			31,879
Total		32,775			31,879
Deferred Tax, net		(95,999	)		(142,484	)

Deferred Tax 2021	Opening Balance			Recognized in Profit or Loss			Recognized in Equity		Exchange Differences			Closing Balance
Intangible assets		(252,174	)		199,056			—		1,204			(51,914	)
Deferred unrealized foreign exchange gains		(350,054	)		350,054			—		—			—
Other receivables		—			(127,000	)		—		4,551			(122,449	)
Net operating loss (NOL)		476,363			(443,730	)		—		(754	)		31,879
Total		(125,865	)		(21,620	)		—		5,001			(142,484	)

Deferred Tax 2020	Opening Balance			Recognized in Profit or Loss			Recognized in Equity		Closing Balance
Intangible assets		(212,844	)		(39,330	)		—		(252,174	)
Deferred unrealized foreign exchange gains		—			(350,054	)		—		(350,054	)
Derivative financial asset		(26,156	)		26,156			—		—
Net operating loss (NOL)		91,851			384,512			—		476,363
Total		(147,149	)		21,284			—		(125,865	)

Schedule of tax loss carry forwards

	December 31, 2021		December 31, 2020
Within 1 year		28,909,896		19,575,171
Between 1 and 3 years		50,673,943		56,866,795
Between 3 and 7 years		29,007,049		36,701,692
More than 7 years		1,264,262		870,200
Total		109,855,150		114,013,858

Schedule of tax effect of major unrecognized temporary differences and loss

	December 31, 2021		December 31, 2020
Deductible temporary differences
Employee benefit plan		87,149		113,106
Derivative financial instruments		—		36,973
Other accounts payable		344,822		258,303
Stock option plans		—		—
Total potential tax assets		431,971		408,382
Taxable unrecognized temporary differences
Convertible loan		—		19,359
Total unrecognized potential tax liabilities		—		19,359
Offsetting potential tax liabilities with potential tax assets		—		(19,359	)
Net potential tax assets from temporary differences not recognized		431,971		389,023
Potential tax assets from loss carry-forwards not recognized		14,271,306		14,896,367
Total potential tax assets from loss carry-forwards and temporary differences not recognized		14,703,277		15,285,390

Sales and Marketing Expense (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Sales And Marketing Expensetext Block Abstract

Schedule of sales and marketing expense

	December 31, 2021		December 31, 2020		December 31, 2019
Marketing and sales expenses		1,132,864		—		—
Employee benefits and expenses		204,157		—		—
Product samples		161,167		—		—
Total sales and marketing		1,498,218		—		—

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property and Equipment [Abstract]

Schedule of property and equipment

	Production equipment			Office furniture and EDP			Total
At cost
As of January 1, 2020		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2020		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2021		353,488			233,706			587,194

Accumulated depreciation
As of January 1, 2020		(290,491	)		(230,031	)		(520,522	)
Charge for the year		(16,481	)		(3,555	)		(20,036	)
Disposals		—			—			—
As of December 31, 2020		(306,972	)		(233,586	)		(540,558	)
Charge for the year		(46,516	)		(119	)		(46,635	)
Disposals		—			—			—
As of December 31, 2021		(353,488	)		(233,705	)		(587,193	)

Net book value
As of December 31, 2020		46,516			120			46,636
As of December 31, 2021		—			1			1

Loan

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Loan [Abstract]

Loan

Loans

On February 4, 2022, the Company entered into a convertible loan agreement (the “Loan Agreement”) with FiveT Investment Management Ltd. (the “Lender”), pursuant to which the Lender has agreed to loan to the Company CHF 5,000,000 (the “Loan”), which Loan bears interest at the rate of 10% per annum and matures 12 months from the date (the “Disbursement Date”) the Loan proceeds were disbursed to the Company, which occurred on February 8, 2022. The Company may prepay all or part of the Loan after six months after the Disbursement Date; provided that the Company will pay an amount equal to 130% of the desired prepayment amount. The Lender has the right to convert all or part of the Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 9.99% of the common shares at any time. The conversion price of the Loan into common shares is USD 38.916, which corresponds to 150% of USD 25.944 (the trading volume weighted average price, the “VWAP”, per common share on the NASDAQ stock exchange on the Disbursement Date), converted into Swiss Francs at the midpoint of the interbank exchange rate shown by UBS on the day of receipt of the conversion notice at 4:00 pm Central European Time. The conversion price shall be lowered in the event that the Company raises equity before the maturity date of the Loan through a public or private offering of common shares at an issue price that is at least 10 (ten) % below the VWAP (the “New Issue”), according to the formula set forth in the Loan Agreement (the “Adjustment”). Sales of common shares through equity line or at-the-market programs are not considered New Issues triggering the Adjustment.

As of June 30, 2022, the carrying amount of the host for the unconverted outstanding loan amounted to CHF 4,701,906 and is included in the balance sheet under current liabilities. The fair value of the embedded derivatives amounted to CHF 284 (at initial recognition February 8, 2022: CHF 449,898) included in current derivative financial instruments. A revaluation gain related to fair value measurement of embedded derivatives of CHF 449,614 as well as effective interest expenses and transaction costs of CHF 359,068 in total were recorded in profit or loss.

Due to the COVID-19 pandemic, Swiss banks granted special COVID-19 loans under certain conditions with a guarantee by the Swiss Government. Our Company was eligible for a loan of CHF 50,000, which was granted on March 26, 2020. The loan is interest-free and may be repaid at any time with a maximum term of five years. We repaid the entire loan as of June 16, 2021.

29. Loan

	December 31, 2021		December 31, 2020
Loan guaranteed by Swiss government (COVID-19)		—		50,000
Convertible loan		—		473,920
Total		—		523,920

Convertible Loan Agreement

	December 31, 2021			December 31, 2020
As of January 1		473,920			—
Gross proceeds at disbursement date		—			1,500,000
Embedded derivative, separated		—			(230,974	)

Transaction costs allocated to host		—			(22,495	)
Carrying amount at initial recognition		—			1,246,531

Converted principal amount		(644,813	)		(895,455	)
Accrued interest at 8%		8,348			31,920
Amortization		162,545			90,924

As of December 31		—			473,920

On September 7, 2020, our affiliate Altamira Medica AG (“Altamira”) and Auris Medical Holding Ltd. (“the Company”) entered into a convertible loan agreement with FiveT Capital Holding AG (“FiveT”) to raise CHF 1,500,000 to fund the initial development of AM-301. The loan has a term of 18 months and carries interest at 8% p.a., which shall not be paid in cash but added to the loan outstanding amount. At maturity, the unconverted outstanding amount of the loan including accrued interest shall become payable in cash. Altamira may choose to repay the total outstanding amount including the accrued interest at 130%, first time after 6 months with a prior written notice of 1 month. Prior to the expiry of the repayment notice period, the lender may convert the repayment amount.

Under the convertible loan agreement FiveT has the right to convert the outstanding principal amount including interest into the Company’s common shares or alternatively into Altamira shares. The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($1.35 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira. By December 31, 2020, an amount of CHF 895,455 has been converted into 737,000 common shares of the Company (at a conversion price of $1.35).

The convertible loan is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used as per December 31, 2020 was 90.9%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability.

The carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivatives. The host is then subsequently measured at amortized cost, using the effective interest rate method. As of December 31, 2020, the carrying amount (including accrued interest) of the host for the unconverted outstanding loan amounted to CHF 473,920 and is included in the balance sheet under current liabilities. On March 4, 2021, the remaining amount of CHF 644,813 including amortization and interest was converted into 516,814 common shares of Altamira at a conversion price of USD 1.35. As a result, the carrying amount of the convertible loan as of December 31, 2021 is CHF 0.

The fair value of the embedded derivatives of the outstanding loan units amounted to CHF 0 (31.12.2020: CHF 310,439 included in current derivative financial instruments). Expenses related to fair value measurement of embedded derivatives of CHF 416,003 (2020: CHF 2,248,257) as well as effective interest and transaction costs of CHF 170,893 (2020: CHF 127,418) were recorded as financial expenses in profit or loss.

Right-of-use assets and lease liabilities

12 Months Ended

Dec. 31, 2021

Right of use assets and lease liabilities [Abstract]

Right-of-use assets and lease liabilities

8. Right-of-use assets and lease liabilities

Right-of-use assets	Office building			Total
At cost
As of January 1, 2020		—			—
As of December 31, 2020		—			—
Additions		594,436			594,436
Disposals		—			—
As of December 31, 2021		594,436			594,436

Accumulated depreciation
As of January 1, 2020		—			—
As of December 31, 2020		—			—
Charge for the year		(29,722	)		(29,722	)
Disposals		—			—
As of December 31, 2021		(29,722	)		(29,722	)

Net book value
As of December 31, 2020		—			—
As of December 31, 2021		564,714			564,714

Low value and short-term lease expenses	December 31, 2021		December 31, 2020

Expense related to short-term leases		52,280		61,509
Expense related to leases of low value assets		—		—
Total		52,280		61,509

Lease liabilities	December 31, 2021			December 31, 2020
As of January 1		—			—
Additions		594,436			—
Interest expenses		3,000			—
Repayment of lease liability		(21,700	)		—
As of December 31		575,736			—

thereof non-current		461,485			—
thereof current		114,251

Maturities of lease liabilities	December 31, 2021			December 31, 2020

Year 1		130,200			—
Year 2		130,200			—
Year 3		130,200			—
Year 4		130,200			—
Year 5		97,650			—
Undiscounted lease payments		618,450			—
Less: unearned interest		(42,714	)		—
Total		575,736			—

Finance Income and Finance Expense (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure of finance income and finance expense [Abstract]

Schedule of finance income and finance expense

	2021			2020		2019
Interest income		3,219			258		17,882
Net foreign currency exchange gain		1,458,429			3,207,649		1,343,153
Revaluation gain from derivative financial instruments		5,085			—		663,725
Total finance income		1,466,733			3,207,907		2,024,760
Interest expense (incl. Bank charges)		189,695			135,151		28,628
Net foreign currency exchange loss		1,129,788			3,541,202		1,562,725
Revaluation loss from derivative financial instruments		416,003			2,250,222		—
Transaction costs		—			219,615		—
Total finance expense		1,735,486			6,146,190		1,591,353
Finance (expense)/income, net		(268,753	)		(2,938,283		433,407

Related party transactions (Details) - CHF (SFr)	12 Months Ended
Related party transactions (Details) - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related party transactions (Details) [Line Items]
Fees paid	SFr 231,770	SFr 173,030
Fees payment for other services	3,025	18,020
Payroll charge	1,210,472	522,237	SFr 934,179
Fees amount	165,245	163,476	170,755
Share based payments	240,408	261,988	159,235
Pension amount	29,467	26,870	42,560
Stock option amount	989,606	769,101	SFr 271,999
Gremaud GmbH [Member]
Related party transactions (Details) [Line Items]
Fees paid	14,720
Fees payment for other services	SFr 161,596	SFr 27,625

Property and Equipment (Details) - Schedule of property and equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 587,194
Additions
Disposals
Property, plant and equipment	587,194	587,194
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(540,558)	(520,522)
Charge for the year	(46,635)	(20,036)
Disposals
Property, plant and equipment	(587,193)	(540,558)
Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	46,636
Property, plant and equipment	1	46,636
Production equipment [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	353,488	353,488
Additions
Disposals
Property, plant and equipment	353,488	353,488
Production equipment [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(306,972)	(290,491)
Charge for the year	(46,516)	(16,481)
Disposals
Property, plant and equipment	(353,488)	(306,972)
Production equipment [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	46,516
Property, plant and equipment		46,516
Office furniture and EDP [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	233,706	233,706
Additions
Disposals
Property, plant and equipment	233,706	233,706
Office furniture and EDP [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(233,586)	(230,031)
Charge for the year	(119)	(3,555)
Disposals
Property, plant and equipment	(233,705)	(233,586)
Office furniture and EDP [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	120
Property, plant and equipment	SFr 1	SFr 120

Write-Down of Inventories (Details)	6 Months Ended
Write-Down of Inventories (Details)	Jun. 30, 2022 CHF (SFr)
Write-down of Inventories [Abstract]
Write down finished goods inventories	SFr 764,844

Capital and Reserves (Details)								1 Months Ended				6 Months Ended			12 Months Ended
Capital and Reserves (Details)	Jun. 01, 2021 USD ($) shares	Mar. 04, 2021	Mar. 04, 2021 CHF (SFr) shares	Dec. 03, 2020	Dec. 01, 2020 CHF (SFr) shares	May 15, 2019 shares	Jan. 24, 2019	Jun. 30, 2021 SFr / shares	Apr. 23, 2020	Nov. 30, 2018 USD ($)	Jan. 30, 2018 shares	Jun. 30, 2022 CHF (SFr) SFr / shares shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 CHF (SFr) SFr / shares shares	Dec. 31, 2021 CHF (SFr) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 CHF (SFr)	Dec. 31, 2019 CHF (SFr)	Jun. 30, 2021 USD ($) shares
Capital and Reserves [Abstract]
Securities purchase agreements description				the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.				the Company completed the acquisition of Trasir. The upfront acquisition price of USD 2.5 million was paid with 764,370 non-registered common shares at USD 3.27 each to the selling shareholders. In addition, 9,173 non-registered common shares were issued to reimburse USD 30,000 in expenses incurred by certain selling Trasir shareholders.
Convertible loan amount (in Francs) \| SFr			SFr 604,545		SFr 895,455
Common shares			516,814		737,000
Conversion price		1.35%	1.35%		1.35%
Interest rate (in Francs) \| SFr			SFr 40,628									SFr 376,848		SFr 172,462	SFr 189,695		SFr 135,151	SFr 28,628
Description of purchase agreement									Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement.
Description of public offering		On March 4, 2021, the remaining convertible loan by FiveT in the amount of CHF 604,545 plus accumulated interests of CHF 40,268 was converted into 25,841 common shares at a conversion price of USD 27.00.				the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised. The remaining 897,435 warrants were exercised in March 2021.
Offering price (in Dollars) \| $																$ 25,000,000
Sale of common stock															1,184,700	1,184,700
Common shares for an aggregate															1,943,318	1,943,318
Proceeds from issue of ordinary shares (in Dollars) \| $										$ 25,000,000						$ 5,400,000
Related transaction costs (in Francs) \| SFr															SFr 71,161
Description of memorandum of continuance							The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.
Upfront acquisition price (in Dollars) \| $	$ 2,500,000
Non registered common shares	38,218
Reference price (in Dollars) \| $	$ 65.4
Additional non registered price	459
Additional reference price (in Dollars) \| $	$ 30,000
Purchase agreement, description									On April 23, 2020, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the 2020 Commitment Purchase Agreement. Through June 30, 2022, we issued a total of 165,000 of our common shares to LPC for an aggregate amount of USD 2,806,605 under the 2020 Commitment Purchase Agreement. During the six months ended June 30, 2022, we issued 105,000 of our common shares to LPC for an aggregate amount of USD 1,698,450 under the 2020 Commitment Purchase Agreement, and as of the date of this report, we have issued a total of 325,000 of our common shares to LPC for an aggregate amount of USD 4,003,820 under the 2020 Commitment Purchase Agreement.
Warrants						44,872
Shares issued												147,166	147,166
Aggregate offering price (in Dollars) \| $													$ 6,700,000
Common share																			87,931
Aggregate offering price (in Dollars) \| $																			$ 2,900,000
Share Capital [Member]
Capital and Reserves [Abstract]
Issued shares												853,213	853,213	682,157
Amount of stock (in Francs) \| SFr												SFr 170,643		SFr 136,431
Nominal value per share (in Francs per share) \| SFr / shares								SFr 0.2				SFr 0.2		SFr 0.2
LPC Agreement [Member]
Capital and Reserves [Abstract]
Purchase agreement, description										On November 30, 2018, as amended on April 5, 2019 the Company entered into a sales agreement, as amended (the “A.G.P. Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”).
AGP Sales Agreement [Member]
Capital and Reserves [Abstract]
Shares issued												228,666	228,666
Aggregate offering price (in Dollars) \| $													$ 7,800,000
Warrants [Member]
Capital and Reserves [Abstract]
Warrants exercisable shares											459
Changes in fair value of warrants issued (in Francs) \| SFr												SFr 1,233			SFr 1,233

Cost of Sales (Details) - Schedule of cost of sales - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Cost Of Sales Abstract
Product purchases, packaging and logistics			SFr 173,758
Employee benefit and expenses			89,238
Inventory write-down			1,977,558
Total cost of sales	SFr 1,192,232		SFr 2,240,554

Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Switzerland [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	5
Closing rate	1	1	1
Average exchange rate	1	1	1
United States [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.911	0.884	0.9674
Average exchange rate	0.9142	0.9581	0.9938
Europe [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	1.0361	1.0817	1.0855
Average exchange rate	1.081	1.0825	1.1128
Australia [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.662	0.6822
Average exchange rate	0.6866	0.6546

Accrued expenses (Details) - Schedule of accrued expenses - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Accrued Expenses Abstract
Accrued research and development costs including milestone payments	SFr 557,391	SFr 1,105,089
Professional fees	179,461	172,273
Accrued vacation & overtime	51,218	44,466
Employee benefits incl. share based payments	196,917	101,821
Other	63,588	9,457
Total accrued expenses	SFr 1,048,575	SFr 1,433,106

Loss per share (Details) - Schedule of loss per share (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Loss Per Share Abstract
Basic and diluted loss per shares	SFr (1.31)	SFr (1.36)	SFr (2.28)

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet	Dec. 31, 2021 USD ($)
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	$ 917,833
Prepayments	996,910
Total current assets	3,759,901
Total assets	18,838,598
Accumulated deficit	(176,018,660)
Total shareholders’ equity attributable to owners of the company	12,704,528
Total equity and liabilities	18,838,598
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	(246,493)
Prepayments	578,216
Total current assets	331,723
Total assets	331,723
Accumulated deficit	331,723
Total shareholders’ equity attributable to owners of the company	331,723
Total equity and liabilities	331,723
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	671,340
Prepayments	1,575,126
Total current assets	4,091,624
Total assets	19,170,321
Accumulated deficit	(175,686,937)
Total shareholders’ equity attributable to owners of the company	13,036,251
Total equity and liabilities	$ 19,170,321

Right-of-use assets and lease liabilities (Details) - Schedule of maturities of lease liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Maturities Of Lease Liabilities Abstract
Year 1	$ 130,200
Year 2	130,200
Year 3	130,200
Year 4	130,200
Year 5	97,650
Undiscounted lease payments	618,450
Less: unearned interest	(42,714)
Total	$ 575,736

Employee Benefits

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Employee benefits [Abstract]

Employee benefits

6.	Employee benefits

	SIX MONTHS ENDED
	JUNE 30,		JUNE 30,
	2022		2021
Salaries		1,439,578		812,158
Pension costs		132,784		66,002
Share based compensation expense		180,808		969,739
Other employee costs and social benefits		157,358		257,108
Total employee benefits		1,910,528		2,105,007

Expenditures for employee benefits increased in the first six months ended June 30, 2022 primarily due to increased headcount compared to the first six months ended June 30, 2021. Share based compensation included expense related to employee stock options of CHF 180,808 in the first six months ended June 30, 2022 compared to CHF 159,487 in the first six months ended June 30, 2021. In 2021, share based compensation expense included CHF 810,252 for a share bonus grant related to the strategic repositioning of the Company, including CHF 360,112 for a future share grant contingent on achieving certain results related to the Trasir transaction.

A total of 27,861 options were granted in the six months ended June 30, 2022 (6,862 options in the corresponding six-month period in 2021). The exercise price of the options granted as share based compensation under the Equity Incentive Plan was USD 20.80 (for the six months ended June 30, 2021 USD 70.20). The methodology for computation of share based compensation expense for the period is consistent with the methodology used in 2021.

23. Employee benefits

	December 31, 2021		December 31, 2020		December 31, 2019
Salaries		1,865,633		1,260,359		1,832,382
Pension costs		165,801		156,843		130,792
Other social benefits		275,258		116,290		217,448
Share based payments costs		1,223,696		351,401		226,601
Other personnel expenditures		214,940		47,295		(22,973	)
Total employee benefits		3,745,328		1,932,188		2,384,250

In 2021 share based compensation expense included CHF 902,817 for one regular and one extraordinary share bonus grant related to the strategic repositioning of the Company. The latter, which amounts to CHF 810,252, including CHF 360,112 for a future share grant contingent on achieving the Positive Results related to the Trasir transaction. Share based compensation included expense related to employee stock options of CHF 320,879 in the year 2021 compared to CHF 351,401 in 2020. On the other hand, expenses for salaries in the previous year had benefited from reimbursements of CHF 63,208 under the Swiss short-time work scheme, which had been used for three months in connection with a temporary reduction in project activities due to the COVID-19 pandemic.

Benefit plans

The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular, also for defining the financing of the pension benefits.

The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.00% in 2019, 1.00% in 2020 and 1.00% in 2021.

The assets are invested by the collective foundation to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants.

For accounting purposes under IFRS, the plan is treated as a defined benefit plan.

The following tables present information about the net defined benefit liability and its components:

Change in defined benefit obligation

	2021			2020
Defined benefit obligation at January 1		3,529,602			3,087,947
Service costs		162,200			151,624
Plan participants’ contribution		101,066			76,032
Interest cost		10,464			9,482
Actuarial losses		159,845			58,912
Plan amendments		(3,115	)		—
Transfer-out amounts		(142,951	)		(201,310	)
Transfer-in amounts of new employees		860,521			346,915
Defined benefit obligation at December 31		4,677,632			3,529,602

The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2021 is 19.9 years (2020: 21.9 years).

Change in fair value of plan assets

	2021			2020
Fair value of plan assets at January 1		2,662,226			2,327,500
Interest income		8,586			7,429
Return on plan assets excluding interest income		424,829			32,794
Employer contributions		101,066			76,032
Plan participants’ contributions		101,066			76,032
Transfer-out amounts		(142,951	)		(201,310	)
Transfer-in amounts of new employees		860,521			346,915
Administration expense		(6,030	)		(3,166	)
Fair value of plan assets at December 31		4,009,313			2,662,226

Net defined benefit liability recognized in the statement of financial position

	December 31, 2021			December 31, 2020
Present value of funded defined benefit obligation		4,677,632			3,529,602
Fair value of plan assets		(4,009,313	)		(2,662,226	)
Net defined benefit liability		668,319			867,376

Defined Benefit Cost

	2021		2020		2019
Service cost		159,085		151,624		138,580
Net interest expense		1,878		2,053		5,137
Administration expense		6,030		3,166		4,051
Total defined costs for the year recognized in profit or loss		166,993		156,843		147,768

Remeasurement of the Defined Benefit Liability

	2021			2020			2019
Actuarial loss (gain) arising from changes in financial assumptions		(74,284	)		13,031			360,541
Actuarial loss (gain) arising from experience adjustments		463,238			45,881			(215,156	)
Actuarial gain arising from demographic assumptions		(229,109	)		—			—
Return on plan assets excluding interest income		(424,829	)		(32,794	)		(73,375	)
Total defined benefit cost for the year recognized in the other comprehensive loss (income)		(264,984	)		26,118			72,010

Assumptions

At December 31	2021			2020			2019
Discount rate		0.30	%		0.20	%		0.30	%
Future salary increase		0.85	%		0.60	%		1.10	%
Pension indexation		0.00	%		0.00	%		0.00	%
Mortality and disability rates		BVG2015G			BVG2015G			BVG2015G

Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below.

December 31,	2021			2020
Change in assumption		0.25% increase			0.25% increase
Discount rate		(200,601	)		(166,228	)
Salary increase		22,961			13,602
Pension indexation		110,958			88,460
Change in assumption		+ 1 year			+ 1 year
Life expectancy		98,983			88,215

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of consolidation

Basis of consolidation

Subsidiaries

Transactions eliminated on consolidation

Segment reporting

Segment reporting

Foreign currency

Foreign currency

Foreign currency transactions

Foreign operations

Closing rates for the most significant foreign currencies relative to CHF:

Currency		Geographical area	Reporting entities		December 31, 2021		December 31, 2020		December 31, 2019
CHF	Swiss Franc	Switzerland		5		1.0000		1.0000		1.0000
USD	Dollar	United States		1		0.9110		0.8840		0.9674
EUR	Euro	Europe		1		1.0361		1.0817		1.0855
AUD	Dollar	Australia		1		0.6620		0.6822		—

Average exchange rates for the year for the most significant foreign currencies relative to CHF:

Currency		Geographical area	Reporting entities		2021		2020		2019
CHF	Swiss Franc	Switzerland		5		1.0000		1.0000		1.0000
USD	Dollar	United States		1		0.9142		0.9581		0.9938
EUR	Euro	Europe		1		1.0810		1.0825		1.1128
AUD	Dollar	Australia		1		0.6866		0.6546		—

Property and equipment

Property and equipment

Production equipment		5 years
Office furniture and electronic data processing equipment (“EDP”)		3 years

Intangible assets

Intangible assets

Research and development

Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred.

Licenses, intellectual property and data rights

Measurement

Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

Subsequent expenditure

Amortization

Impairment of non-financial assets

Impairment of non-financial assets

Asset purchase

Asset purchase

Leases

Leases

Right-of-use assets

Lease liabilities

Short-term leases and leases of low-value assets

Inventories

Inventories

Financial instruments

Financial instruments

Recognition and derecognition of non-derivative financial assets and liabilities

The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired.

Non-derivative financial assets and liabilities—measurement

Loans and receivable

Cash and cash equivalents

Non-derivative financial liabilities—measurement

Convertible loans

Share capital

The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Repurchase and reissue of ordinary shares (treasury shares)

Impairment of non-derivative financial assets

Impairment of non-derivative financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence that financial assets are impaired includes:

●

default or delinquency by a debtor;

●

indications that a debtor or issuer will enter bankruptcy;

●

adverse changes in the payment status of borrowers or issuers;

●

the disappearance of an active market for a security; or

●

observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets.

Financial assets measured at amortized cost

Derivative Financial Instruments

Derivative Financial Instruments

Embedded Derivatives

Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when:

The host contract is not an asset in the scope of IFRS 9

The host contract is not itself carried at fair value through profit and loss (FVPL)

The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract

The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host

Income tax

Income tax

Current tax

Deferred tax

●

temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

●

taxable temporary differences arising on the initial recognition of goodwill.

Employee benefits

Employee benefits

Share-based compensation

Share-based compensation

Valuation of share options

Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.

Provisions

Revenue recognition

Revenue recognition

Government grants

Government grants

Earnings/(loss) per share

Earnings/(loss) per share

Trade and Other Payables (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Trade And Other Payables Text Block Abstract

Schedule of trade and other payables

	December 31, 2021		December 31, 2020
Trade accounts payable - third parties		3,544,384		722,272
Other		153,339		40,181
Total trade and other payables		3,697,723		762,453

Basis of preparation

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

Disclosure Of Basis Of Preparation Of Financial Statements Text Block Abstract

Basis of preparation

2.	Basis of preparation

Statement of compliance

These condensed consolidated interim financial statements as of June 30, 2022 and for the six months ended June 30, 2022 have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting (“IAS 34”) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021.

These condensed consolidated interim financial statements include all adjustments that are necessary to fairly state the results of the interim period. The Group believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. Management does not consider the business to be seasonal or cyclical.

Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board, have been condensed or omitted as permitted by IAS 34. The condensed consolidated statement of financial position as of December 31, 2021 was derived from the audited consolidated financial statements.

The interim condensed consolidated financial statements were authorized for issuance by the Company’s Audit Committee on November 28, 2022

Functional and reporting currency

These interim condensed consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional currency (“functional currency”) and the Group’s reporting currency.

Significant accounting policies

The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its audited consolidated financial statements as of and for the year ended December 31, 2021 and have been applied consistently to all periods presented in these condensed consolidated interim financial statements, unless otherwise indicated.

New standards, amendments and interpretations adopted by the Group

	Amendments to IAS 16	Property, Plant and Equipment: Proceeds before Intended Use
	Amendments to IAS 37	Provisions, Contingent Liabilities and Contingent Assets - Onerous contracts – Costs of fulfilling a Contract
	Amendments to IFRS 3	Business Combinations - Reference to the Conceptual Framework
	Annual Improvements to IFRS Standards 2018-2020 – Amendments to IFRS 1, IFRS 9, IFRS 16, IAS 41

The application of these new standards, amendments to standards and interpretations does not have material impact on the financial statements of the Group.

Convertible loan

The convertible loan obtained from FiveT Investment Management Ltd. (see Note 5) is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach.

Intangible assets

As of June 30, 2022, Intangible assets amounted to CHF 15,851,501, compared to CHF 14,314,877 as of December 31, 2021. The increase is due to the capitalization of development costs related to the AM-125 program.

Going concern

The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares. To the extent that we will be unable to generate sufficient cash proceeds from the planned divestiture or spin-off of our legacy assets or other partnering activities, we will need substantial additional financing to meet these funding requirements both through the fourth quarter of 2022 and thereafter. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements have been prepared on a going concern basis, which contemplates the continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, in particular the intended divestiture or spin-off of the Company’s legacy assets in the fields of inner ear therapeutics and OTC consumer health products, and from other sources of revenue such as grant funding.

On October 21, 2022, the Company announced the sale of (i) 90% of the share capital of its subsidiary Zilentin AG and (ii) an option to purchase the subsidiaries Auris Medical AG, Otolanum AG, Auris Medical Ltd. and Auris Medical Pty Ltd (the “Additional Subsidiaries”) – representing the Company’s inner ear therapeutic assets – to a European family office (the “Buyer”) for a cash consideration of USD 1 million each, for a total of USD 2 million (the “Zilentin Transaction”). Under the terms of the option agreement (the “Option”) Zilentin will be entitled to purchase the Additional Subsidiaries for an upfront payment of USD 25. million plus potential milestone royalty payments. The Option may be exercised for 30 days from October 19, 2022 (the “Closing Date”); beyond that period, Zilentin will have a right of first refusal to acquire these companies until year end with the upfront payment increasing by USD 1 million per month. There is no assurance that Buyer will exercise its option, triggering the additional upfront payment of USD 25 million. Due to a delay in the closing of the Zilentin Transaction, the Company and the Buyer agreed on November 23, 2022 to amend their agreement, extending the Closing Date to December 15, 2022 at the latest, increasing the share capital of Zilentin AG to be sold under the transaction from 90 to 100% and raising the amount of the initial payment for the purchase of Zilentin and for the option to purchase the Additional Subsidiaries from USD 2 million to USD 2.2 million.

The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. Apart from the inner ear therapeutic assets, the Company intends to spin off or divest also its OTC consumer health products business, in order to focus on the development of its OligoPhore/SemaPhore RNA delivery platform. At the date of issuing these financial statements, such plans have not yet been realized.

Accordingly, the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realize its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements.

The Company plans to secure additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations. Such matters are not within the control of the Company and thus all associated outcomes are uncertain.

Accounting for divestiture

From the date of entering into the agreement for the disposal of Zilentin and the sale of the purchase option for the Additional Subsidiaries, the respective assets and liabilities are classified as held for sale and measured at the lower of carrying amount and fair value less costs to sell. As the agreement was entered into after June 30, 2022, and consequently the criteria for held for sale were met only after the reporting period, the disposal group is presented in the subsequent events and not yet as held for sale in the financial statements. The assets held for sale mainly comprise capitalized development costs related to the AM-125 program, which amounted to CHF 12.0 million as of June 30, 2022.

2. Basis of preparation

Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”).

These consolidated financial statements were approved by the Board of Directors and the Audit Committee of the Company on April 7, 2022.

Basis of measurement

The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

●

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

●

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

●

Level 3 inputs are unobservable inputs for the asset or liability.

Functional and reporting currency

These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Group’s reporting currency.

Redomestication

The Redomestication of the Company from Switzerland to Bermuda is a continuance of its business. Therefore, the consolidated financial statements present the operation of Auris Medical Holding AG for the time before the Redomestication and of Auris Medical Holding Ltd for the time following the Redomestication.

2019 Reverse Share Split

The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20. No fractional common shares were issued as fractional common shares were settled in cash. Impacted amounts and share information included in the consolidated financial statements and notes thereto have been adjusted for the reverse share split as if such reverse share split occurred on the first day of the periods presented. Certain amounts in the notes to the consolidated financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse share split.

Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below.

Income taxes

As disclosed in Note 25 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose.

The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law.

Other than a tax asset in the amount of CHF 31,879 (31.12.2020: CHF 476,363), the Group has not recorded any deferred tax assets in relation to these tax losses. Deferred tax assets on tax losses were only considered to the extent that they offset taxable temporary differences within the same entity. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax loss reflects the reassessment of deferred tax assets and liabilities booked in the 2021 fiscal year.

Development expenditures

The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. We do not capitalize clinical development expenditures until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. For the Group’s intranasal betahistine program for the treatment of vertigo (AM-125), however, the development is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and aims to demonstrate higher bioavailability through intranasal delivery. Given the nature of the development approach and the fact that there is an existing market in which oral betahistine for the treatment of vertigo has been approved, direct development expenditures have been capitalized.

As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost.

Employee benefits

The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy.

Research and Development and Accrued Expenses

The Company records the costs associated with research, nonclinical and clinical trials, and manufacturing process development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities being conducted by third party service providers, including contract research and manufacturing organizations.

The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accrued expenses are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrued expense balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as prepayments which will be expensed as the contracted services are performed. Inputs, such as the services performed, the number of patients enrolled, or the trial duration, may vary from the Company’s estimates. As actual costs become known, the Company adjusts its prepayments and accrued expenses.

Intangible assets (Details) - Schedule of intangible assets - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
At cost
At cost, Beginning Balance		SFr 6,765,613
At cost, Exchange differences	SFr (3,654)	6,120
At cost, Additions	6,733,050	2,343,677
At cost, Ending Balance	15,844,806	9,115,410
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(1,529,929)
Accumulated amortization and impairment losses, Ending Balance	(1,529,929)
Net book value
Net book value	14,314,877	9,115,410
Licenses [Member]
At cost
At cost, Beginning Balance		1,482,520
At cost, Exchange differences
At cost, Additions	3,893,681
At cost, Ending Balance	5,376,201	1,482,520
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(1,482,520)
Accumulated amortization and impairment losses, Ending Balance	(1,482,520)
Net book value
Net book value	3,893,681	1,482,520
IP & Data rights [Member]
At cost
At cost, Beginning Balance		193,989
At cost, Exchange differences
At cost, Additions
At cost, Ending Balance	193,989	193,989
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(47,409)
Accumulated amortization and impairment losses, Ending Balance	(47,409)
Net book value
Net book value	146,580	193,989
Patents [Member]
At cost
At cost, Beginning Balance		239,593
At cost, Exchange differences
At cost, Additions	55,938	177,623
At cost, Ending Balance	473,154	417,216
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment
Accumulated amortization and impairment losses, Ending Balance
Net book value
Net book value	473,154	417,216
Internally generated [Member]
At cost
At cost, Beginning Balance		4,849,511
At cost, Exchange differences	(3,654)	6,120
At cost, Additions	2,783,431	2,166,054
At cost, Ending Balance	9,801,462	7,021,685
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment
Accumulated amortization and impairment losses, Ending Balance
Net book value
Net book value	SFr 9,801,462	SFr 7,021,685

Capital and Reserves (Details) - Schedule of issued share capital - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number		14,964,261	11,417,159
Value (CHF)	SFr 170,643	SFr 149,643	SFr 114,172
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number		14,964,261	11,417,159
Value (CHF)		SFr 149,643	SFr 114,172

Significant accounting policies (Details)	12 Months Ended
Significant accounting policies (Details)	Dec. 31, 2021 USD ($)	Jun. 01, 2021
Significant accounting policies (Details) [Line Items]
Number of operating segments	1
Share capital percentage		100.00%
Asset purchase description	The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price.
Minimum royalty term	12 years
Aggregate amount	$ 4,375,000
License agreement description	The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.
Short-term leases and leases of low-value assets description	The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.
Description of equity incentive plan	Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.
Research and development expenditures percentage	43.50%
License [Member]
Significant accounting policies (Details) [Line Items]
Estimated useful life	10 years

Trade and Other Payables (Details) - Schedule of trade and other payables - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Trade And Other Payables Abstract
Trade accounts payable - third parties		SFr 3,544,384	SFr 722,272
Other		153,339	40,181
Total trade and other payables	SFr 3,164,754	SFr 3,697,723	SFr 762,453

Finance Income and Finance Expense (Details) - Schedule of finance income and finance expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Finance Income and Finance Expense [Abstract]
Interest income	SFr 3,219	SFr 258	SFr 17,882
Net foreign currency exchange gain	1,458,429	3,207,649	1,343,153
Revaluation gain from derivative financial instruments	5,085		663,725
Total finance income	1,466,733	3,207,907	2,024,760
Interest expense (incl. Bank charges)	189,695	135,151	28,628
Net foreign currency exchange loss	1,129,788	3,541,202	1,562,725
Revaluation loss from derivative financial instruments	416,003	2,250,222
Transaction costs		219,615
Total finance expense	1,735,486	6,146,190	1,591,353
Finance (expense)/income, net	SFr (268,753)	SFr 2,938,283	SFr 433,407

Share-based compensation (Details) - Schedule of fair value of the options measured - USD ($)

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Equity Incentive Plan 2021 [Member] | One Year Vesting Period [Member]

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[1]

USD 0.932 (2 year vesting) 1) USD 1.107 (3 year vesting) 1)

USD 1.64

USD 1.889

93.40%

2 and 3 years

Equity Incentive Plan 2021 [Member] | Two Year Vesting Period [Member]

0.47%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[2]

USD 1.241 (1 year vesting) 2) USD 1.850 (2 year vesting) 2) USD 2.183 (3 year vesting) 2)

USD 3.54

USD 3.511

101.30%

1, 2 and 3 years

Equity Incentive Plan 2020 [Member] | One Year Vesting Period [Member]

0.06%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[1]

USD 0.325 (2 year vesting) 1) USD 0.391 (3 year vesting) 1)

USD 0.79

USD 0.878

84.96%

2 and 3 years

Equity Incentive Plan 2020 [Member] | Two Year Vesting Period [Member]

0.82%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[2]

USD 0.258 (1 year vesting) 2) USD 0.514 (2 year vesting) 2) USD 0.578 (3 year vesting) 2)

USD 0.92

USD 0.825

72.72%

1, 2 and 3 years